Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 3
1966 1
1967 6
1968 3
1969 3
1970 1
1971 4
1972 3
1973 3
1974 3
1975 4
1976 2
1977 1
1978 6
1979 4
1980 5
1981 2
1983 2
1984 1
1985 2
1986 3
1987 8
1988 3
1989 2
1990 5
1991 7
1992 5
1993 3
1994 5
1995 6
1996 5
1997 2
2000 1
2001 3
2002 1
2003 2
2004 7
2005 10
2006 7
2007 10
2008 12
2009 9
2010 11
2011 19
2012 21
2013 18
2014 19
2015 13
2016 7
2017 12
2018 14
2019 28
2020 14
2021 25
2022 23
2023 23
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

381 results

Results by year

Filters applied: . Clear all
Page 1
Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis.
Kawamura S, Matsushita Y, Kurosaki S, Tange M, Fujiwara N, Hayata Y, Hayakawa Y, Suzuki N, Hata M, Tsuboi M, Kishikawa T, Kinoshita H, Nakatsuka T, Sato M, Kudo Y, Hoshida Y, Umemura A, Eguchi A, Ikenoue T, Hirata Y, Uesugi M, Tateishi R, Tateishi K, Fujishiro M, Koike K, Nakagawa H. Kawamura S, et al. Among authors: tateishi r. J Clin Invest. 2022 Jun 1;132(11):e151895. doi: 10.1172/JCI151895. J Clin Invest. 2022. PMID: 35380992 Free PMC article.
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Kudo M, et al. Among authors: tateishi r. Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19. Liver Cancer. 2021. PMID: 34239808 Free PMC article. Review.
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.
Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, Panda G, Qian T, Zhu S, Goossens N, Wang X, Liang S, Zhong Z, Lewis S, Taouli B, Schwartz ME, Fiel MI, Singal AG, Marrero JA, Fobar AJ, Parikh ND, Raman I, Li QZ, Taguri M, Ono A, Aikata H, Nakahara T, Nakagawa H, Matsushita Y, Tateishi R, Koike K, Kobayashi M, Higashi T, Nakagawa S, Yamashita YI, Beppu T, Baba H, Kumada H, Chayama K, Baumert TF, Hoshida Y. Fujiwara N, et al. Among authors: tateishi r. Sci Transl Med. 2022 Jun 22;14(650):eabo4474. doi: 10.1126/scitranslmed.abo4474. Epub 2022 Jun 22. Sci Transl Med. 2022. PMID: 35731891 Free PMC article.
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Omata M, et al. Among authors: tateishi r. Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. Epub 2017 Jun 15. Hepatol Int. 2017. PMID: 28620797 Free PMC article. Review.
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines).
Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, Shimada M, Nagano H, Hatano E, Aikata H, Iijima H, Ueshima K, Ohkawa K, Genda T, Tsuchiya K, Torimura T, Ikeda M, Furuse J, Akahane M, Kobayashi S, Sakurai H, Takeda A, Murakami T, Motosugi U, Matsuyama Y, Kudo M, Tateishi R; committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan. Hasegawa K, et al. Among authors: tateishi r. Hepatol Res. 2023 May;53(5):383-390. doi: 10.1111/hepr.13892. Epub 2023 Mar 10. Hepatol Res. 2023. PMID: 36826411
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. Yamashita T, et al. Among authors: tateishi r. J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12. J Gastroenterol. 2020. PMID: 31720835 Free PMC article. Clinical Trial.
Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial).
Takayama T, Hasegawa K, Izumi N, Kudo M, Shimada M, Yamanaka N, Inomata M, Kaneko S, Nakayama H, Kawaguchi Y, Kashiwabara K, Tateishi R, Shiina S, Koike K, Matsuyama Y, Omata M, Makuuchi M, Kokudo N. Takayama T, et al. Among authors: tateishi r. Liver Cancer. 2021 Dec 29;11(3):209-218. doi: 10.1159/000521665. eCollection 2022 Jun. Liver Cancer. 2021. PMID: 35949295 Free PMC article.
CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.
Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakatsuka T, Tanaka Y, Tateishi R, Hikiba Y, Misumi K, Tanaka M, Hayashi A, Shibahara J, Fukayama M, Arita J, Hasegawa K, Hirschfield H, Hoshida Y, Hirata Y, Otsuka M, Tateishi K, Koike K. Fujiwara N, et al. Among authors: tateishi r. Gut. 2018 Aug;67(8):1493-1504. doi: 10.1136/gutjnl-2017-315193. Epub 2018 Feb 6. Gut. 2018. PMID: 29437870 Free PMC article.
The Era of the Hepatic Oncologist.
Tateishi R. Tateishi R. Liver Cancer. 2020 Aug;9(4):378-381. doi: 10.1159/000508342. Epub 2020 Jun 3. Liver Cancer. 2020. PMID: 32999865 Free PMC article. No abstract available.
Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma.
Yamada T, Fujiwara N, Kubota N, Matsushita Y, Nakatsuka T, Kurosaki S, Minami T, Tateishi R, Ichida A, Arita J, Hasegawa K, Koike K, Fujishiro M, Nakagawa H. Yamada T, et al. Among authors: tateishi r. Hepatol Commun. 2023 Jul 17;7(8):e0209. doi: 10.1097/HC9.0000000000000209. eCollection 2023 Aug 1. Hepatol Commun. 2023. PMID: 37471053 Free PMC article.
381 results